Stage IV Non-Small Cell Lung Cancer without Driver Alterations
Key Points
Key Points
This clinical practice guideline update addresses two overarching clinical questions:
- What are the most effective first-line treatment options for patients with stage IV NSCLC without driver alterations, based on cancer subtype?
- What are the most effective second-line and subsequent treatment options for patients with stage IV NSCLC without driver alterations based on cancer subtype?
Treatment
Treatmen...
...recommendations with multiple treatment...
...Question 1: What are the most effe...
...us Cell Carcinoma (Non-SCC)...
...with programmed death-ligand 1 or progra...
1.1. For patients with a programmed d...
...ts with a programmed death-ligand 1 o...
...ents with a programmed death-ligand 1 or progr...
...For patients with a programmed death-ligand...
...atients with a programmed death-ligand 1 or prog...
...ts with a programmed death-ligand 1 or...
...with PD-L1 expression TPS, 1â€...
.... For patients with PD-L1 expression TPS, 1...
....8. For patients with PD-L1 expression TPS, 1â...
...r patients with PD-L1 expression T...
...For patients with PD-L1 expression T...
...ients with PD-L1 expression TPS, 1–49%, cli...
...2. For patients who are ineligible for or decl...
...nknown or negative PD-L1 expression, TPS...
...patients with unknown or negative PD-L...
...For patients with unknown or negative PD-L1...
...For patients with unknown or negative PD-...
...r patients with unknown or negative PD-L1 expre...
...ients with unknown or negative PD-L1...
...Cell Carcinoma (SCC)...
...atients with PD-L1 expression...
...or patients with PD-L1 expression, TPS ≥50%,,...
...r patients with PD-L1 expression,...
...or patients with PD-L1 expression, TP...
...tients with PD-L1 expression, TPS ≥50%, clinic...
...or patients with PD-L1 expression, TPS â...
...ith PD-L1 expression TPS, 1–49%:...
...patients with PD-L1 expression TPS, 1–49%...
...atients with PD-L1 expression TPS, 1...
....8. For patients with PD-L1 expres...
...patients with PD-L1 expression TPS, 1–...
...ents with PD-L1 expression TPS, 1–49% w...
...tients with unknown or negative PD-L1...
...r patients with unknown or negative PD-L1 expre...
...patients with unknown or negative PD-L1 exp...
...r patients with unknown or negative PD-L1 expressi...
...tients with unknown or negative PD-L1 expression,...
...atients with Unspecified Histo...
...patients with unknown or negative...
...ients with unknown or negative PD-L1 expre...
...ients with unknown or negative PD-...
...vacizumab should be avoided for patie...
...atients with contraindications to beva...
...with Unspecified Histology...
...cizumab should be avoided for pati...
...intenance bevacizumab given with pemetrexed has...
...al Question 2: What are the most eff...
...viously treated with immune checkpoint...
...For patients previously treated with immu...
...reviously treated with chemotherapy and immune...
...s previously treated with chemothera...
5.2. In patients previously treated with chemothe...
...gure 1. Second-Line and Subsequent Treat...
...First-Line Treatment Options for...
...st-Line Treatment Options for Patients Wit...